Gastrointestinal tract plasmablastic lymphoma in HIV infected adults: a histopathological audit. by Mwazha, Absalom.
  
 
 
 
 
 
GASTROINTESTINAL TRACT PLASMABLASTIC LYMPHOMA  
IN 
 HIV INFECTED ADULTS:  
A HISTOPATHOLOGICAL AUDIT 
 
 
by 
ABSALOM MWAZHA 
Student Number: 214584095 
 
 
Submitted in partial fulfilment of the requirements for the degree of 
MASTER OF MEDICINE 
in the 
Department of Anatomical Pathology 
School of Laboratory Medicine and Medical Sciences 
Nelson R Mandela School of Medicine 
University of KwaZulu-Natal 
Durban 
 
January 2020 
i 
 
DECLARATION 
 
I, Dr Absalom Mwazha, declare as follows:  
i. The research reported in this dissertation/thesis, except where otherwise indicated, 
is my original research.  
ii. This dissertation/thesis has not been submitted for any degree or examination at any 
other university. 
iii. This dissertation/thesis does not contain other persons’ data, pictures, graphs or 
other information, unless specifically acknowledged as being sourced from other 
persons. 
iv. This dissertation/thesis does not contain other persons’ writing, unless specifically 
acknowledged as being sourced from other researchers.  
v. Where other written sources have been quoted, then: 
a. their words have been re-written but the general information attributed to 
them has been referenced; 
b. where their exact words have been used, their writing has been placed inside 
quotation marks, and referenced. 
vi. This dissertation/thesis does not contain text, graphics or tables copied and pasted 
from the Internet, unless specifically acknowledged, and the source being detailed in 
the dissertation/thesis and in the References sections. 
Student Number:   214584095                      Signature:  
 
Date: 21st of January 2020 
 
 
ii 
 
DEDICATION 
 
This work is dedicated with gratitude to my father Runokovangwa Corneus Mwazha and to 
my mentors. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
iii 
 
ACKNOWLEDGEMENTS 
 
 
I am truly grateful to my supervisor Dr GB Nhlonzi for his invaluable assistance, guidance, 
patience and trust in my abilities throughout this project. 
 
I sincerely thank Professor PK Ramdial for inspiring the initiation of this project and her 
critical insight from which I benefited at every stage of this project. 
 
To the laboratory staff at Inkosi Albert Luthuli Central Hospital, I give my thanks for their 
assistance. I would like to specifically acknowledge the cooperation and support from Ms. 
Audrey Mzizi, Mr. Sadiki Kabala and Mr. Dinesh Sookhdeo for laboratory assistance and Mrs. 
M Moodley for administrative assistance. 
 
My heartfelt thanks are due to all my friends and family for their patience, support and 
helping to keep me sane. 
 
 
 
 
 
 
 
 
 
 
iv 
 
ABSTRACT 
 
Background: Plasmablastic lymphoma (PBL) is an aggressive B-cell lymphoma that is 
characterised by the expression of plasma cell antigens and loss of pan B-cell antigens. The 
neoplasm is extensively reported in the oral cavity and anorectal region but rarely in the 
gastrointestinal tract where only isolated case reports and small case series exist. In the 
current study, morphologic, immunohistochemical and molecular features of 17 cases of 
gastrointestinal tract PBL were reviewed.    
Materials and Methods: Ten-year retrospective study that reappraised the 
histomorphological and immunophenotypic features of HIV-associated PBLs in the 
gastrointestinal tract that were diagnosed and coded as ‘plasmablastic lymphoma’. 
Results: The average age of the study patients was 41 years with a 3:1 ratio of males to 
females. The most frequent site of involvement was the small intestine (42%). Majority of 
the cases showed a predominant diffuse (82%) growth pattern. Immunoblasts and 
plasmablasts were observed in all cases. Sixty-five percent (65%) of the cases exhibited 
scattered centroblasts and one case demonstrated predominance of centroblasts. Other 
features observed include pseudo-alveolar growth pattern, plasmacytic differentiation, 
scattered multinucleated giant cells, focal clear cell change, high mitotic activity with high 
proliferative indices (Ki-67 >90%), apoptotic bodies and necrosis. Immunohistochemistry 
revealed absence of pan B-cell antigens and expression of plasma cell antigens. Epstein-Barr 
virus-encoded RNA was expressed in 53% of the cases. 
Conclusion: This study highlights the spectrum of histopathological features of 
gastrointestinal tract PBLs. Additional observations not previously described or emphasised 
in literature includes pseudo-alveolar growth pattern, centroblast-predominance, 
multinucleated giant cells and clear cell change. Awareness of this entity in the 
gastrointestinal tract and its histopathological features and immunohistochemical profile is 
essential for making an accurate diagnosis and avoiding potential diagnostic errors. 
Keywords: Plasmablastic lymphoma; HIV-related lymphoma; AIDS-related lymphoma; 
gastrointestinal tract; stomach; small intestine; colon 
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CHAPTER 1 
 
 
1. INTRODUCTION  
 
Lymphomas which arise in human immunodeficiency virus (HIV) positive patients are 
heterogeneous and include those which are usually diagnosed in immunocompetent 
patients as well as those that are commonly seen in the setting of HIV infection [1]. The HIV-
associated lymphomas commonly encountered include Burkitt lymphoma (BL), diffuse large 
B-cell lymphoma (DLBCL), primary effusion lymphoma (PEL) and plasmablastic lymphoma 
(PBL) [1]. 
 
Plasmablastic lymphoma (PBL) is an aggressive high-grade B-cell non-Hodgkin lymphoma 
characterised by the proliferation of large B-cell immunoblast-like neoplastic cells that 
demonstrate plasma cell differentiation associated with loss of conventional B-cell antigens 
[2,3].  Delecluse et al [4] originally described PBL in HIV-positive patients as a subtype of 
diffuse large B-cell lymphoma confined to the oral cavity. The neoplastic cells display 
frequent association with Epstein-Barr virus (EBV) infection.  EBV-encoded RNA (EBER) in-
situ hybridisation positivity has been described in 60-75% of PBLs [2,5]. HIV-positive patients 
frequently have more EBV-positive PBLs compared with HIV-negative patients [5-6].  
 
PBLs have also been reported in the anorectal region, gastrointestinal tract, skin, lung, 
nasopharynx, paranasal sinuses, lymph nodes, breast, central nervous system and soft 
tissues [7-8]. 
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Several studies have also reported on PBLs in HIV-negative patients with and without 
immunosuppression [9-12]. PBLs arising in HIV-negative and HIV-positive patients have 
different clinicopathological characteristics which include younger age, male predominance 
and better response to chemotherapy in HIV-associated PBLs [9].  
 
PBLs can be subdivided into two morphologic subgroups including lymphomas comprised of 
a monomorphic population of immunoblasts and lymphomas with plasmacytic 
differentiation composed of immunoblasts, plasmablasts and cells showing plasma cell 
differentiation [2,8].  Extra-oral PBLs are associated with non HIV-related 
immunosuppression and commonly display plasmacytic differentiation [8]. 
 
Cytogenetic studies have found c-MYC translocation in 50% of PBLs cases and this is 
associated with MYC-protein overexpression [2,13]. EBV-positive neoplasms are more likely 
to have c-MYC rearrangements when compared to EBV-negative neoplasms [13].  
 
A considerable body of literature on oral plasmablastic lymphoma is available [4,14-17]. 
However, the histopathological features and descriptions of extra-oral PBLs are infrequently 
reported particularly in the stomach, small intestine and colon. The reports currently 
available include isolated cases and small series of up to 4 cases [18-26]. As a result, there is 
a need for a comprehensive examination of PBLs in these segments of the gastrointestinal 
tract to broaden the reported cases and improve on diagnostic accuracy and promote early 
intervention. 
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CHAPTER 2 
 
2. AIM AND OBJECTIVES 
 
2.1. Aim of Study 
The aim of this study was to assess the histopathological spectrum of gastrointestinal 
tract plasmablastic lymphomas in HIV-infected adult patients. 
 
2.2. Specific Objectives 
The objectives were to assess:  
i. the histomorphological heterogeneity, if any; 
ii. the immunophenotypic profile;  
iii. the EBV status; 
iv. the cytogenetic alterations. 
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CHAPTER 3 
 
 
3. LITERATURE REVIEW 
 
3.1. Definition of Plasmablastic Lymphoma 
 
Plasmablastic lymphoma is an aggressive, high-grade B-cell non-Hodgkin lymphoma 
characterised by diffuse proliferation of large neoplastic cells which resemble B-cell 
immunoblasts [2]. The neoplastic cells display terminal B-cell or plasma cell differentiation 
associated with acquisition of a variety of plasma cell antigens and loss of conventional B-
cell antigens [2,27-28]. 
 
3.2. Classification of Plasmablastic Lymphoma 
 
The WHO Classification of Haematopoietic and Lymphoid Tumours classifies neoplasms 
mainly according to their cell of origin, after which distinct disease entities within each 
category are further defined according to their histomorphology, immunophenotypic profile 
and cytogenetic alterations. 
 
 The World Health Organisation (WHO) classifies plasmablastic lymphoma as a separate 
entity, distinct from DLBCL under mature B-cell neoplasms [2] (Table 3.1). 
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Table 3.1: WHO classification of mature B-cell neoplasms. (Adapted from the 2017 WHO 
classification of haematopoietic and lymphoid tumours) 
 
3.3. History 
 
Delecluse et al [4] originally described plasmablastic lymphoma in HIV-positive patients as a 
subtype of diffuse large B-cell lymphoma confined to the oral cavity. The neoplastic cells 
showed unusual immunophenotype (weak or absent CD45 and CD20), and frequent EBV 
positivity. The tumour cells expressed characteristic plasma cell markers (MUM-1, VS38c, 
CD79a).  The B-cell nature of the neoplastic cells was confirmed by cytoplasmic expression 
of immunoglobulins (Ig) and monoclonal rearrangements of the Ig heavy chain genes. In 
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2008, this lymphoma was reclassified as a separate diagnostic entity, distinct from diffuse 
large B-cell lymphoma (DLBCL), not otherwise specified [2]. 
 
Subsequently, plasmablastic lymphomas have been reported at extra-oral sites such as 
anorectal region, gastrointestinal tract, skin, lung, nasopharynx, paranasal sinuses, lymph 
nodes, breast, mediastinum, central nervous system and soft tissues [7,29 -32]. The oral 
cavity however still remains the preferred site of involvement by PBL.   
 
Several studies have reported on PBLs in immunocompetent and immunosuppressed HIV-
negative patients [9,33]. PBLs arising in HIV-positive and HIV-negative patients have been 
shown to have different clinicopathological characteristics. HIV-positive patients have been 
shown to have better response to chemotherapy and better overall prognosis [9]. 
Similarities and differences have also been identified in clinicopathological characteristics of 
oral and extra-oral plasmablastic lymphomas (EPBL). Oral cavity PBLs have been found to be 
associated with HIV infection and plasmablastic morphology with no plasmacytic 
differentiation. Extra-oral plasmablastic lymphoma has been found to be associated with 
non-HIV related immunosuppression and commonly display plasmacytic differentiation [10]. 
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3.4. Aetiopathogenesis 
 
The aetiopathogenesis of this tumour has not yet been fully elucidated, but the plasmablast 
is known to be the cell of origin [3]. The current thinking is that the plasmablast is derived 
from a post-germinal centre B-cell that has undergone preterminal differentiation via 
somatic hypermutation and class switching recombination to resemble a plasma cell rather 
than a B-cell [3,16,28]. 
 
Cytogenetic alterations which have been reported include rearrangements involving c-MYC 
and the immunoglobulin gene and strong association with EBV infection [13] 
Most studies have failed to show any association between plasmablastic lymphoma and 
Kaposi sarcoma-associated herpesvirus (KSHV) or human herpesvirus 8 (HHV8) [27]. 
 
3.5. HIV Infection 
 
Human immunodeficiency virus (HIV) infection has been linked to increased risk of 
developing haematolymphoid disorders. Primary central nervous system lymphoma 
(PCNSL), primary effusion lymphoma (PEL), and plasmablastic lymphoma are some of the 
histopathological subtypes commonly encountered in HIV-infected patients [1].  
 
Castillo et al [9] in a large review of 228 patients with plasmablastic lymphoma found 69% of 
the patients to be HIV-positive and 31% to be HIV-negative. Amongst the HIV-negative 
patients, approximately a third of the patients had some form of immunosuppression such 
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as an organ transplant or elderly with presumptive immunosenescence. The remainder of 
the patients with plasmablastic lymphoma were HIV-negative and immunocompetent 
[9,33]. 
 
In HIV-positive patients, several pathogenetic mechanisms such as chronic antigen 
stimulation, cytokine deregulation (Interleukin 6) and the role of EBV and HHV8 have been 
proposed [1].  HIV-infected macrophages up-regulate the expression of Interleukin 6 (IL-6) 
which is an important plasma cell growth factor [34-35]. 
 EBV and/or HHV-8 infection, which are common in HIV-infected patients, are also 
associated with high serum levels of IL-6 which may further explain the common association 
of plasma cell neoplasms in HIV-patients [34-35]. 
 
3.6. Clinical Features  
 
HIV-associated oral PBL is recorded in literature as occurring more frequently in males and 
at a mean age of 39 years [36-38]. Conflicting reports on the mean age and sex preference 
have reported in the published case reports and small case series of gastrointestinal PBL.  
Luria et al [25] in a review of published cases of gastrointestinal PBL, reported a mean 
patient age of 57 years (range: 17 - 82 years) with a male-to-female ratio of 3:4. 
Komaranchath et al [23] reported on four cases which showed a mean age of 29.5 years 
(range: 13 - 45 years) with a male-to-female ratio of 3:1. 
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The oral lesions on the palatal mucosa and gingiva typically present as rapidly growing fleshy 
masses [4, 37,38]. In extra-oral locations, plasmablastic lymphoma present, most commonly 
as mucocutaneous masses, which may ulcerate or bleed [2,9]. Generalised 
lymphadenopathy is an unusual clinical presentation [2,9]. In the gastrointestinal tract, the 
common presentations include non-specific abdominal symptoms associated with polypoid 
masses or ulcerating masses [22-24]. 
According to Lurai et al [25], locations of the primary lesions within the gastrointestinal tract 
consist of the stomach (43%), small intestine (21%), anal region (21%), caecum (14%), colon 
(7%), and oesophagus (7%) [25]. 
 
3.7. Morphology  
 
The characteristic immunoblasts exhibit abundant basophilic cytoplasm with occasional 
paranuclear hofs, round and oval nuclei with vesicular chromatin and prominent central 
nucleoli, while the plasmablasts show eccentrically placed nuclei with coarse chromatin and 
small conspicuous nucleoli [4,8,38-40].  
 
Tumours showing plasmacytic differentiation show a predominant population of 
plasmablasts/immunoblasts with a small component of small plasma cells containing a 
clock-face chromatin pattern, amphophilic cytoplasm and a paranuclear hof [8]. 
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Figure 3.1: Illustration of a plasmablast 
 
PBLs can be subdivided into two morphological subgroups based on cellular features. The 
first group ‘PBL of the oral mucosa type’ is composed of a monomorphic population of 
plasmablasts/immunoblast with no/minimal plasmacytic differentiation (2,8). The other 
group, ‘PBL with plasmacytoid differentiation’ shows plasmacytic differentiation and is 
composed of plasmablasts and cells showing plasma cell differentiation (2,8). 
 
The presence of scattered tingible body macrophages result in a “starry-sky” appearance 
[2]. Background small mature lymphocytes, brisk mitotic activity, apoptotic bodies and 
necrosis are common features in PBL of the oral cavity [2,4].  
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3.8. Immunophenotype 
 
The neoplastic cells of PBLs show immunophenotypic profile compatible with late or 
terminally differentiated B-cell type. The tumour cells show weak or no expression of 
leukocyte common antigen (CD45) and loss of mature B-cell markers (CD20, CD19 and PAX5) 
[4,8].  However, the plasma cell markers (VS38c, CD38, MUM1, EMA and CD138) are 
expressed [2,41]. CD79a and CD30 are also frequently positive and Cyclin D1 is negative. 
CD56 is detected in 25% of cases [2].  
 
Cytoplasmic immunoglobulins (usually IgG) and immunoglobulin light chain restriction 
(kappa or lambda) suggestive of clonality have been described in PBLs [2].   
   
The phenomenon of T-cell infidelity in which PBLs, which are B-cell lymphomas, express T-
cell antigens (CD3, CD4, CD43, and CD7) is well described [18,42,43]. The proposed possible 
mechanisms of this lineage ambiguity include trans-differentiation and downregulation of B-
cell transcription factors (particularly PAX5) [44]. CD3 expression in CD20+ B-cell lymphomas 
is usually not problematic since co-expression of these two markers will prompt further 
workup with more lineage-specific markers and molecular studies. However in cases when 
common B-cell antigens (CD20 and PAX5) are negative, T-cell infidelity may result in the 
tumour being classified as a peripheral T-cell lymphoma, not otherwise specified (PTCL 
NOS). 
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Plasmablastic lymphomas are a high grade neoplasm with associated high proliferation 
indices (Ki-67/MIB1) of >90% [2]. 
3.1. EBV Status  
 
The exact relationship between EBV status and PBL is still evolving. In EBV-infected B-cells, 
the linear viral genome becomes circular and persists within the cells as an episome. The 
virus can express genes in two distinct programmes, the latent or lytic cycle [45]. 
 A limited set of genes are expressed during the latent cycle and these include EBV nuclear 
antigens (EBNAs) 1, 2, 3A, 3B, 3C and leader protein (LP) and three latent membrane 
proteins (LMPs), which are associated with transforming activity [45].  
 
EBV-associated neoplastic diseases can be divided into three patterns of latency depending 
on the viral genes expressed [27]. In Type I (e.g. Burkitt lymphoma), only EBNA-1, non-
translated EBV-encoded RNAs (EBERs) and BamH1 A rightward transcripts (BARTs) are 
expressed. Type II (e.g. Hodgkin lymphoma and primary effusion lymphoma) expresses 
EBNA-1, LMP1, LMP2, EBERs and BARTs. In type III (e.g. post-transplant lymphoproliferative 
disorders, PTLD), all latency genes are expressed.  
 
LMP1 is the major transforming protein of EBV and upregulates expression of the anti-
apoptotic proteins Bcl-2 and A20, and stimulates cytokine production (IL-6 and IL-8) [45].  
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EBNA-1 is a nuclear phosphoprotein that allows the EBV genome to be maintained in the B-
cell by binding to viral DNA [46]. EBNA-2 is a viral transcription factor that enhances the 
growth and transformation of B-cells by inducing expression of LMP1 and LMP2 [47].  EBNA-
3s upregulate expression of cellular proteins [38]. EBERs do not encode for any protein but 
are thought to be important in oncogenesis and resistance to apoptosis [47]. 
 
Delecluse et al [4] originally described the association between plasmablastic lymphoma 
and latent EBV infection. The World Health Organisation (WHO) Classification cites EBER ISH 
as positive in 60 - 75% of cases [2]. A higher association (86%) between PBL and EBV was 
also reported by Castillo et al [9] who showed that 82% of the HIV-positive cases and 46% of 
the HIV-negative cases, displayed expression of EBER by ISH.  EBV infection is higher in PBL 
classified as ‘PBL of the oral mucosa type’ as compared to incidence in ‘PBL with plasmacytic 
differentiation [2,34]. Majority of the PBL cases have shown a type-1 EBV latency pattern 
[49,50]. EBV has also been detected in 15% of cases of extramedullary plasma cell tumours 
of the head and neck in immunocompetent patients [8].  
 
3.2. Cytogenetic Studies 
 
Conventional cytogenetic studies typically reveal clonal rearrangement of IGH and 
polyclonal T-cell receptor (TCR). The other molecular alterations which have been identified 
are c-MYC-translocation and MYC-amplification [13]. Translocation involving MYC gene has 
been reported in 60% of plasmablastic lymphoma cases and this results in MYC-protein 
overexpression [13]. The partner for MYC is IGH in most cases (>90%) [5,28,51-53].  MYC 
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rearrangements are more commonly found in the EBV-positive cases (74%) than in the EBV-
negative cases (43%) [13]. The MYC rearrangements have also been found to be more 
common in HIV-positive patients [53]. 
A recent study has demonstrated recurrent somatic mutations in PRDM1 in 50% of 
plasmablastic lymphoma cases (8 of 16 cases evaluated) [41]. PRDM1 normally helps in 
regulation of MYC and is also a driver of terminal B-cell differentiation. Mutation of PRDM1 
in the setting of PBL may contribute to dysregulation of MYC, while apparently retaining the 
capacity to induce terminal B-cell differentiation [41].  
 
Cytogenetic studies have not detected rearrangements of oncogenes altered in other 
lymphomas (BCL2, BCL6, MALT1, and PAX5) [13]. 
 
3.3. Differential Diagnosis 
 
Diagnostic challenges for PBL may arise in the gastrointestinal tract due to its morphology, 
lack of expression of CD45 and pan-B cell markers and occasional T-cell infidelity. This 
immunophenotype can inadvertently lead to the exclusion of lymphoma from the 
differential diagnoses.  Misdiagnosis of gastrointestinal tract PBL would have a great impact 
on treatment strategy and clinical outcome. 
 
Morphologically, the neoplasm may mimic a diffuse large B-cell lymphoma (DLBL), 
anaplastic lymphoma kinase (ALK) positive large B-cell lymphoma, extracavitary primary 
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effusion lymphoma (EPEL), plasmablastic myeloma, poorly differentiated 
carcinoma(including colorectal carcinoma) and melanoma [54]. 
 
Diffuse large B-cell lymphoma not otherwise specified (DLBCL NOS) may have similar 
morphological features to PBL but is distinguished from PBL through its expression of pan-B-
cell markers (CD20, CD19, CD79a, PAX5) [55-57]. The tumour cells in DLBCL NOS may not 
express one or more of these pan B-cell markers [57]. 
 
ALK-positive large B cell lymphoma is a rare aggressive neoplasm composed of ALK-positive, 
large monomorphic immunoblast-like B-cells [58-59]. The cells usually lack pan B-cell 
markers (CD20, CD19, CD79a and PAX5) and express plasma cell phenotype (MUM-1, VS38c, 
CD138). All the cases are also EBV and HHV8 negative [58-59].   
 
Extracavitary primary effusion lymphoma (PEL) and PBL have overlapping histopathological 
features and immunophenotypic profile, however, the presence of HHV8 infection supports 
the diagnosis of extracavitary PEL [60-62]. Extracavitary PEL displays a higher expression of 
CD20 and CD79a when compared to PBLs [60-62]. 
 
Differentiating PBL from plasmablastic myeloma remains a major diagnostic challenge and is 
at times impossible. The two entities may have similar morphology, immunophenotype and 
more importantly clinical features [63]. Some have proposed that PBL may actually 
represent an aggressive form of multiple myeloma or plasmacytoma [63]. The presence of a 
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high proliferative index (Ki-67) and EBV infection favours PBL whilst immunopositivity for 
Cyclin D1, CD117 and CD56 favours a plasmablastic myeloma [2, 63,64]. The absence of 
serum monoclonal proteins, osteolytic bone lesions and/ or bone marrow involvement, the 
presence of EBV infection, HIV/AIDS-related immunodeficiency, and the aggressive clinical 
course favours the diagnosis of PBL above other plasma cell neoplasms [63]. However 
multiple myeloma has also been described in HIV/AIDS patients with or without EBV 
infection [53,63,65]. 
 
The combination of CD45, pan T-cell and pan B-cell marker immunonegativity, associated 
with EMA immunopositivity may lead to a diagnostic pitfall of an undifferentiated 
carcinoma. Carcinomas will however show positivity for broad-spectrum cytokeratin and not 
express plasma cell markers (MUM1, Vs38c, CD138) or show kappa light chain restriction.  
Aberrant cytokeratin expression has been reported in a small subset of PBLs [33,67]. 
Aberrant CD138 staining has also be described in undifferentiated carcinomas [67]. 
 
Based on immunohistochemical profile a, melanoma can be excluded as it stains with S100, 
Melan A, HMB45, MiTF and SOX10, all of which are negative in PBLs. 
 
3.4. Treatment and Prognosis 
 
The tumour is highly aggressive with poor response to therapy and short survival despite 
aggressive therapy combining highly active anti-retroviral (HAART), systemic chemotherapy 
and /or radiotherapy. 
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Cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) and CHOP-like regimens 
are considered inadequate due to highly aggressive nature of the neoplasm, more intensive 
regimens, such as infusional EPOCH (etoposide, vincristine, doxorubicin, cyclophosphamide, 
and prednisone) have been recommended *36+. Due to the lack of CD20 expression by 
plasmablastic cells, the use of rituximab, an anti-CD20 monoclonal antibody, is not currently 
a therapeutic standard *8+. 
 
 Patients with plasmablastic lymphoma and HIV infection have been found to have an 
overall survival of 14 months compared to 9 months in HIV-negative patients [9]. 
 
3.5. Current Status 
 
Few cases of gastrointestinal tract plasmablastic lymphoma have been reported globally.   
The diagnosis is commonly based on morphological features and immunohistochemical 
profile seen at the commonly described sites.   
 
The gastrointestinal tract is a unique location with its own specific differential diagnoses 
which have to be considered in this location. This study therefore seeks to assess the 
histomorphological spectrum of plasmablastic lymphoma in the gastrointestinal tract and to 
highlight the microscopic pitfalls and mimicry, if any.   
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CHAPTER 4 
 
 
 
4. MATERIALS AND METHODS 
 
 
4.1. Study Population 
 
 
The study design was that of a laboratory-based retrospective study which involved 
purposive sampling and evaluation of all biopsies diagnosed and coded as ‘plasmablastic 
lymphoma’ from 1st January 2009 to 31st December 2018. 
The cases were accessed from the archive of the Department of Anatomical Pathology, 
Inkosi Albert Luthuli Central Hospital (IALCH), National Health Laboratory Service (NHLS), 
and School of Laboratory Medicine and Clinical Sciences, Durban, KwaZulu-Natal, South 
Africa, using the SNOMED word and code search engines. 
 
 
 
4.2. Study Sample and Sampling Strategy  
 
 
This retrospective study included all cases diagnosed as PBL from the gastrointestinal tract 
(oesophagus, stomach, small intestine and colon) from 1st January 2009 to 31st December 
2018.  A total of 18 cases were retrieved from the departmental archives.   
 
On histopathological and immunohistochemical profile review, one case was re-classified as 
diffuse large B-cell lymphoma (DLBCL). This case was excluded from the study. The study 
sample then comprised 17 cases of gastrointestinal tract PBL.  
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Demographic data extracted from the NHLS laboratory information system (Trakcare) and 
histopathology reports of the patients included their age, gender, HIV status and biopsy site 
(stomach, small intestine and colon). Tumour size was also retrieved from the 
histopathology reports. 
 
 
4.3. Inclusion / Exclusion Criteria 
 
 
The inclusion criteria were those cases from HIV-positive patients that had a 
histopathological and immunophenotypic profile compatible with a diagnosis of PBL and 
that appeared to have occurred along the gastrointestinal tract site as ascertained from the 
demographic data available on the histopathology reports and microscopic features. 
Patients with plasmablastic lymphoma from the oral cavity and anorectal region were 
excluded from the study. 
 
4.4. Data Collection Methods and Tools 
 
 
Stored haematoxylin and eosin (H&E) stained sections, immunohistochemical sections and 
cytogenetics study images were reappraised. Patient slides were allocated study numbers in 
order to maintain patient confidentiality. Two pathologists (A.M, G.N) independently 
reappraised stored sections on Olympus BX43 (Olympus, Tokyo, Japan) microscopes. 
Whenever a discrepancy occurred, both investigators re-examined the slides to reach a 
consensus. Data sheets were used for data collection. 
The diagnostic criteria that were used for the confirmation of PBL included a high-grade 
neoplasm consisting of cells demonstrating variable immunoblastic, plasmablastic and/or 
plasmacytic features. In addition, the neoplastic cells were expected to demonstrate CD20 
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immunonegativity and at least one plasma cell marker (MUM-1, VS38c, CD138) 
immunopositivity. The characteristic immunoblast exhibit round to oval nuclei with vesicular 
chromatin and prominent central nucleoli while the plasmablast show eccentrically placed 
nuclei with coarse chromatin and small conspicuous nucleoli [8]. Tumours showing 
plasmacytic differentiation show a predominant population of plasmablasts/immunoblast 
with a small component of small plasma cells containing a clock-face chromatin pattern, 
amphophilic cytoplasm and a paranuclear hof [8]. 
 
 
4.4.1. Histomorphology 
 
 
The original 4μm-thick haematoxylin and eosin (H&E) stained slides were reviewed to 
evaluate the following histopathologic features: architectural growth patterns (diffuse, 
nodular, trabecular and/or single cells) and cytomorphology (plasmablast, immunoblast, 
centroblast and presence of plasmacytic differentiation). The mitotic activity (expressed as 
mitotic figures per 10 high power fields in the most mitotic area, using a 40 X objective and 
a 10 X ocular lens; field area: 0.237 mm2),apoptotic bodies and tumour necrosis were also 
evaluated.   
 
Where necessary, re-cuts at 4μm were done from formalin-fixed paraffin embedded (FFPE) 
archived tissue blocks. Re-staining of archived slides was also done in some cases where the 
paraffin-embedded archived blocks could not be retrieved or when there was no residual 
tissue on the block. 
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4.4.2. Immunohistochemistry 
Immunohistochemical slides used to establish the initial diagnosis by the primary 
pathologist were reviewed. Immunohistochemical stains commonly assessed on the 
biopsies include LCA (CD45), CD3, CD20, MUM1/IRF4, CD138, VS38c, CD79a, PAX5, CD30, 
HHV8, ALK-1, AE1/AE3, CAM 5.2 and MNF116.   
 
Where necessary and sufficient tissue available, stains were repeated using manufacturer’s 
instructions on an automated immunostainer (Ventana Benchmark Ultra, Tucson, AZ). The 
repeat immunohistochemistry monoclonal antibodies were performed on formalin-fixed 
paraffin embedded 3-μm sections (Table 4.1). Appropriate positive controls were used 
throughout. 
RTU: Ready to use 
 
Table 4.1 List of antibodies used for immunophenotypic analysis 
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Supplier Information  
Dako - Glostrup, Denmark  
BD Biosciences - San Jose, CA, USA 
Roche -Basel, Switzerland 
Abcam - Cambridge, United Kingdom 
Cell Marque - Rocklin, CA, USA 
 
Brown granular staining either on cell nucleus (MUM1/IRF4, Ki-67/MIB1, PAX5), cell 
membrane (CD138, CD45, CD20, CD3) or in cell cytoplasm (VS38c, ALK-1, CD79a, AE1/AE3, 
CAM 5.2, MNF116) was regarded as positive.  
 
Cases were considered as positive for MUM1/IRF4 if 30% or more of the tumour cells were 
positively stained by the antibody, as described in the study by Hans et al *68+. The results 
for the rest of the markers were recorded and positive or negative.   
Qualitative scoring of the intensity of staining was categorised as follows: “negative” (−), 
“weak” (+), “moderate”(++), and “strong”(+++) [69]. 
 
The proliferation index was assessed using Ki-67. Ki-67 was assessed by counting positive 
and negative cells in 5 high power fields, averaging and then converting to a percentage.  
 
The archived IHC stains were utilised despite the fact that they lacked standardisation in-
terms of antibody clonality, dilution and antigen retrieval methods. This was due to the 
financial implications which would have resulted from repeating the stains.   
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Some of the stains had been run manually using in-house modification of internationally 
recognised protocols with appropriate positive and negative controls. 
 
4.4.3. Epstein-Barr Virus in-situ Hybridisation Studies 
 
 
EBER staining assessment was done using stored slides which formed part of the diagnostic 
case record.    
 
If necessary and where sufficient material was available, staining was repeated. 
Chromogen in situ hybridisation was performed on 3-μm-thick sections for Epstein-Barr 
virus–encoded RNA (EBER) (INFORM EBER Probe, Ventana Medical Systems, Tucson, AZ, 
USA).Slides were stained on an automated immunostainer (Ventana Benchmark Ultra, 
Tucson, AZ) and for visualisation the ISH iView Blue Detection Kit (Ventana Medical Systems) 
with alkaline phosphatase was used. Nuclear Fast Red (Ventana Medical Systems) was 
employed for contrast.  
Appropriate positive controls were used throughout. A positive signal appeared as an 
intense blue density of the cell nucleus. The result was recorded as either EBER positive or 
negative. 
 
 
4.4.4. Cytogenetic Studies 
 
 
Digital images for cytogenetic studies results were reviewed for two cases on which they 
had been conducted successfully. Fluorescence in-situ hybridisation (FISH) was performed 
with Vysis LSI MYC dual-colour, break-apart rearrangement probe (Abbott Molecular, Des 
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Plaines, IL, USA) and was carried out on 4μm-thick formalin-fixed, paraffin-embedded tissue 
sections following manufacturer’s guidelines. DAPI (4′, 6-diamidino-2-phenylindole) was 
used as a nuclear counterstain.  
 
Results were evaluated on an Olympus BX61 (Olympus, Tokyo, Japan) immunofluorescence 
microscope using appropriate filters. Images were captured with Cytovision 4.0 (Leica 
Biosystems Inc., Buffalo Grove, IL, USA). 
A normal nucleus hybridised with the LSI MYC Dual Colour Break Apart Rearrangement 
Probe displays a pattern of two orange/green fusion signals. In a cell with a translocation 
breakpoint, one green, one orange and one fusion signal pattern should be observed. The 
cut-off value for a positive result with the LSI MYC probe in the study was 10%. 
 
Immunoglobulin gene rearrangements were investigated by polymerase chain reaction 
(PCR) on formalin-fixed, paraffin-embedded tissue according to the departmental standard 
operating procedures at that time, for one of the cases. 
 
 
 
4.5. Study Location  
 
 
This study was conducted in the laboratory of the Department of Anatomical pathology of 
the National Health Laboratory Service (NHLS) and University of KwaZulu-Natal, Inkosi 
Albert Luthuli Central Hospital (IALCH), Durban, South Africa. 
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4.6. Ethical Considerations 
 
The Biomedical Research Ethics Committee of the University of KwaZulu-Natal approved the 
study (BREC Ref No: BE016/19). Furthermore, permission was also granted by the 
Department of Health (DOH), Province of KwaZulu-Natal and National Health Laboratory 
Service (NHLS) to retrieve and use archived material and data. 
 
4.1. Data Analysis Techniques 
 
The study design was that of a retrospective study that was based on descriptive 
demographics, histomorphological, immunohistochemical and in-situ hybridisation (ISH) 
data. Computerised statistical analysis and interpretation was performed using Stata 15.0 
statistical software (Stata Corp LP, College Station, TX, USA). The data was descriptive and 
variably continuous and categorical, consisting of frequencies that were expressed in 
percentages and ratios to summarise data. Descriptive statistics included calculations of 
means.  Differences in means between groups were evaluated using two sample, two-tailed 
t-tests. In all instances, a p-value of less than 0.05 was considered statistically significant. 
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CHAPTER 5 
 
 
5. RESULTS 
 
 
5.1. Study Sample  
 
 
A total of eighteen (18) cases diagnosed as gastrointestinal tract PBL were retrieved from 
the archives of the Department of Anatomical Pathology, National Health Laboratory 
Service, University of KwaZulu-Natal, Durban over a ten-year period between January 2009 
to December 2018. One case was reclassified as a diffuse large B-cell lymphoma (DLBL) and 
excluded from the study, leaving seventeen (17) cases that made up the study cohort. 
 
5.2. Patient Demographics  
 
 
5.2.1. Sex 
 
 
Thirteen (76%) patients were males (M) and only four (24%) were females (F). There was a 
male bias with a male-to-female of 3:1 (Figure.5.1). 
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Figure 5.1: Sex distribution in patients with gastrointestinal PBL 
 
 
 
5.2.2. Age 
 
Age was documented for 16 of the 17 patients recruited into the study cohort. 
Gastrointestinal tract PBL documented over the study period occurred between the ages of 
29 and 68 years (mean 41 years, 95% CI = 35.35 - 46.65) (Figure.5.2). The mean age of 
females in the study population was 30 years (95% CI = 26.82 - 38.7) and the mean age of 
males was 44 years (95% CI = 38.53 – 50.80). The difference in mean age between males 
and females was statistically significant (two sample t-test, p = 0.003). 
 
24% 
76% 
Female Male
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Figure 5.2: Age distribution in males and females with gastrointestinal tract PBL 
 
5.3. Nature of Biopsy 
 
 
The biopsies were either endoscopic incisional biopsies (53%, 9/17) or excisional biopsies 
(47%, 8/17). 
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5.4. Anatomical Location  
 
 
 
The gastrointestinal tract locations of the tumours, upon which the primary diagnosis was 
made at presentation, are listed in Table 5.1. Information regarding the tumour site was 
indicated in the macroscopic descriptions in the histopathology reports. 
 
 
 
Table 5.1: Summary of the clinical features of PBL cases included in the study 
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Gastrointestinal tract PBL occurred most commonly in the small intestines (42 %, 7/17) then 
stomach (29%, 5/17) and the colon (29%, 5/17). 
 
5.5. Gross Pathology 
 
Minimal details on the gross appearance of the tumours were retrieved from the 
histopathology reports. Details on gross tumour size were available for six of the eight 
excisional biopsies. The tumours ranged in size from 3 to 8 cm (mean 5.5 cm; 95% CI = 3.54 - 
7.46). 
 
 
5.6. Histopathological Features 
 
 
5.6.1. Architectural patterns 
 
 
On microscopic appraisal, the neoplasm showed one or more architectural patterns with 
diffuse architecture being the most common (82%, 14/17), followed by scattered single cells 
(29%, 5/17), multinodular (24%, 4/17), trabecular (18%, 3/17) and pseudo-alveolar (12%, 
2/17) growth patterns (Fig. 5.3 - 5.8).  A low power “starry-sky” pattern was seen in the 
majority of excision biopsy specimens (75%, 6/8) (Figure 5.3). The incision biopsy specimens 
showed starry-sky appearance in 56% (5/9) of the cases. 
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Figure 5.3: PBL with a starry-sky appearance imparted by interspersed tingible body 
macrophages (arrows) (H&E, X100 magnification) 
 
 
 
 
Figure 5.4: Small biopsy showing PBL with diffuse architecture (H&E, X100 magnification) 
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Figure 5.5: PBL with a multinodular architecture (H&E, X100 magnification) 
 
Figure 5.6: PBL with a trabeculae architecture (H&E, X100 magnification) 
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Figure 5.7: PBL with tumour cells infiltrating lamina propria as single cells (arrows) (H&E, 
X200 magnification) 
 
Figure 5.8: PBL with a pseudo-alveolar growth pattern (H&E X100 magnification) 
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5.1.1. Cytomorphology 
 
 
 
All cases showed proliferation of large lymphoid cells with immunoblastic and plasmablastic 
morphology with occasional presence of paranuclear hof (Figures 5.9 - 11). Plasmacytic 
differentiation was identified in 29% (5/17) of the cases (Figure 5.12). Scattered centroblasts 
were identified in 11 (65%) cases. One case showed centroblasts as the predominant cell 
type (Figure 5.13). The majority of cases (71%) showed amphophilic cytoplasm while the 
remaining 29% exhibited eosinophilic cytoplasm. Two cases showed focal clear cell change 
(Figure 5.14). Scattered multinucleated tumour giant cells were observed in two cases 
(Figure 5.15). 
 
 
Figure 5.9: PBL showing a plasmablastic morphology (H&E, magnification X400) 
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Figure 5.10:  PBL showing a plasmablastic morphology (H&E, magnification X400) 
 
Figure 5.11:  PBL showing a plasmablastic and immunoblastic morphology (H&E, 
magnification X400) 
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Figure 5.12: PBL with plasmablastic phenotype and plasmacytic differentiation (arrows) 
(H&E, magnification X400) 
 
Figure 5.13: PBL showing neoplastic cells with multiple nucleoli in keeping with 
centroblastic morphology (H&E, magnification X400) 
37 
 
 
Figure 5.14: PBL showing neoplastic cells with focal cytoplasmic clearing (H&E, 
magnification X400) 
 
Figure 5.15:  PBL showing scattered multinucleated giant cells (arrow) (H&E, magnification 
X400) 
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All cases in the present study had identifiable mitotic figures, ranging from 16 to 62 (mean 
32) per ten high power fields. Apoptotic bodies were observed in all biopsies and these were 
arranged as single cells or as confluent areas of apoptotic bodies. Necrosis was evident in 
71% (12/17) of the biopsies. 
 
5.1. Immunohistochemical findings 
 
Summarised in Table 5.2 are the immunohistochemical results. 
Key: +/−: Weak positive, +: Positive, −Negative, ND: Not done CK: Cytokeratin (AE1/3, CAM5.2, MNF116) 
Table 5.2: Immunohistochemical characteristics of the gastrointestinal tract PBL cases 
 
CD45/Leucocyte common antigen (LCA):CD45 stained positively in 59% of the cases (10/17) 
and was negative in 41% (7/17). Staining was membranous and was invariably weak. 
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CD3: Staining was negative in 94% of the cases (16/17), being positive in only one case 
which showed T-cell infidelity (Figure 5.16). Background reactive T-cells were identified in all 
the cases. 
 CD20: All the cases in this study were negative for this pan B-cell marker (Figure 5.17). 
PAX 5 displayed focal weak nuclear staining in one (20%, 1/5) case. The rest of the cases 
were negative (80%, 4/5) for PAX5. 
MUM-1:  MUM-1 antibody was positive in 88% (14/16) of the cases (Figure.5.18).  The 
staining was nuclear in location, diffuse and moderate to strong in intensity. 
VS38c: Eleven (11) of 14 (fourteen) cases (79%) which were tested with this antibody were 
positive (Figure.5.19).   Staining was cytoplasmic in location, diffuse in distribution and 
strong in intensity. 
CD138: All the eight cases (100%) tested with CD138 were positive (Figure.5.20). Staining 
was cytoplasmic in location, diffuse in distribution and strong in intensity. 
Human Herpes Virus-8: All of the 8 cases tested with this antibody were negative (Figure 
5.21).  Confirmed cases of Kaposi sarcoma were used as the external positive control. 
ALK-1: All 10 cases (100%) in which this antibody was tested were negative (Figure 5.22)  
The Ki-67 proliferative index examined in thirteen cases was high (>90%) in all the cases 
(Figure 3.23). The positive signal was nuclear in location, of moderate to strong intensity. 
Thirty-three percent (5/15) of the cases showed patchy immunopositivity for CD30.  All 
cases which were tested for broad-spectrum cytokeratins (7/17) and CD56 (3/17) were 
negative.  
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Figure 5.16: PBL demonstrating negative staining of tumour cells (CD3, magnification 
X400) 
 
Figure 5.17: PBL showing negative staining of the tumour cells (CD20, magnification X400) 
41 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.18 PBL showing positive nuclear staining of tumour cells (MUM1, magnification 
X400) 
 
Figure 5.19: PBL demonstrating positive cytoplasmic staining in tumour cells (VS38c, 
magnification X400) 
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Figure 5.20: PBL demonstrating positive membranous staining in tumour cells (CD138, 
magnification X400) 
 
Figure 5.21: PBL demonstrating negative staining of the tumour cells (ALK-1, magnification 
X400) 
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Figure 5.22 PBL showing negative staining of the neoplastic cells (HHV8, magnification 
X400) 
 
Figure 5.23:  PBL showing positive nuclear expression in >90% of the tumour cells (Ki-67, 
magnification X400) 
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5.1. EBV Status 
 
 
EBV status: In-situ hybridisation, for EBER was positive in 53% (9/17) of the cases under 
review (Figure 5.13). The positive signal was nuclear in location and had a deep blue colour. 
 
 
Figure 5.24 PBL showing nuclear expression in tumour cells (EBER ISH, magnification X400) 
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5.2. Cytogenetic Studies 
 
Fluorescence in-situ hybridisation (FISH) for c-MYC rearrangements was successfully 
performed on one case which showed c-MYC translocation.  BCL2 and BCL6 were intact. The 
case which had c-MYC translocation also had EBER ISH positivity. One case showed 
immunoglobulin heavy (IGH) chain clonality. The other cases in the study did not have 
cytogenetic analysis done (11/17) or it was unsuccessfully attempted (4/17). 
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CHAPTER 6 
 
 
6. DISCUSSION 
 
Plasmablastic lymphoma (PBL) is a highly aggressive CD20 negative B-cell lymphoma that is 
increasingly reported in HIV-positive patients [2,70]. Although originally described in the 
oral cavity of HIV positive patients, occurrence in other sites and HIV-negative patients has 
been documented [3,7,9]. The neoplastic cells display terminal B-cell or plasma cell 
differentiation associated with acquisition of a variety of plasma cell antigens and loss of 
conventional B-cell antigens [2,3,28].  
 
The majority of the gastrointestinal tract PBLs have been described in the stomach, small 
intestine and colon as case reports and small case series [18-26]. Herein, we report on 17 
patients with gastrointestinal tract PBLs focusing on the morphological and 
immunohistochemical features. 
 
The age of the patients with gastrointestinal tract PBL in this series ranged between 29 to 68 
years with a mean age at diagnosis of 41 years, which is similar to that reported in oral PBL 
[4-5,12,36-38]. Females were significantly younger than males (mean age 30 vs. 44 years).  
There were no paediatric gastrointestinal tract PBL cases reported during the study period.  
 The male predominance (male-to-female ratio of 3:1) is similar to what has been reported 
in oral PBL and in one small case series of gastrointestinal tract PBL [16,23,36].   
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All the patients in the study were HIV-positive (as per inclusion criteria). However, it is 
important to note that, none of the gastrointestinal tract PBL which were retrieved from the 
departmental archives were from HIV-negative patients. The strong relationship between 
HIV-infection and PBLs is well documented and PBL is recognised as one of the HIV-
associated lymphomas [1,71]. The pathogenesis of HIV-related lymphomas has been 
attributed to chronic antigen stimulation, cytokine (IL-6) deregulation and the role of EBV 
and HHV8 co-infection [1]. Highly active antiretroviral therapy does not appear to have an 
impact on this increased risk of developing HIV-associated haematolymphoid neoplasms 
[72]. 
 
The PBL neoplasms in this case series occurred in the stomach (29%), small intestines (42%) 
and the colon (29%). A systematic review of publications on gastrointestinal tract PBLs 
reported between 1993 and 2013 found 14 cases of which the stomach (43%) was the 
predominant location followed by the anal region (21%) and small intestine (21%) [25]. 
 
The major histopathological features of PBLs include a predominantly diffuse growth 
pattern, “starry-sky” appearance on low power, necrosis, apoptotic cells, and neoplastic 
cells showing predominantly immunoblastic and plasmablastic cytomorphology. The 
characteristic immunoblastic cells exhibit round to oval nuclei with vesicular chromatin and 
prominent central nucleoli while the plasmablastic cells show eccentrically placed nuclei 
with coarse chromatin and small conspicuous nucleoli [8]. The findings of the present study 
showed comparable features to those reported in the case studies and series on 
gastrointestinal tract PBLs [18-26]. 
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Plasmacytic differentiation with a predominant population of plasmablasts/immunoblasts 
with a small component of small plasma cells containing a clock-face chromatin pattern, 
amphophilic cytoplasm and a paranuclear hof was evident in 29% of the cases. Though 
other reports have suggested that plasmacytic differentiation occurs more preferentially in 
extra-oral sites [10], others have not supported such observations [8,73].   
 
In the current study, one case of PBL was notable for a predominance of centroblasts with 
multiple peripheral nucleoli. In the current study, one case of PBL was notable for a 
predominance of centroblasts with multiple peripheral nucleoli. Similar features were 
reported in a previous case on oral cavity PBL with predominant centroblastic morphology 
*74+. Hirosawa et al *74+ reported on a case of oral cavity PBL that showed proliferation of 
large cells with centroblastic morphology. The observation of predominant centroblasts in a 
case of gastrointestinal tract PBL, to the best of our knowledge, has not been previously 
described. 
 
In small endoscopic incisional biopsies, neoplastic cells may show trabecular and single cell 
growth patterns and less frequently show “starry-sky” appearance. The diagnosis of PBL in 
these circumstances becomes a challenge as the pathologist is constrained with limited 
amounts of tissue (for morphology and immunohistochemical workup) and marked biopsy 
artefacts commonly associated with small biopsies. 
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An unusual histopathological growth pattern identified in two of the present cases is the 
pseudo-alveolar growth pattern. Vaubell et al *75+ in their report on paediatric PBL cases 
described pseudo-alveolar growth pattern in some of their cases.  This pattern seems to 
have been observed in excision biopsies, which suggest the possibility that this could have 
been due to tissue fixation artefact. However it remains an important pattern to recognise in 
PBL in this location so as to avoid misdiagnosis.   
 
Two cases in the current study were remarkable for the striking clear cell features of the 
tumour cells, a feature that, to our knowledge, has not been previously described in 
gastrointestinal PBL. There are only a few cases of clear cell lymphomas described in the 
literature, including diffuse large B-cell lymphoma and primary cutaneous anaplastic 
lymphoma *76-78+. The origin of the clearing of the cells in this case is not clear and may 
represent a tissue fixation artefact. 
 
Multinucleated giant cells, similar to those of our cases, have been described in T-cell-rich 
large B-cell lymphoma, peripheral T-cell lymphoma, angioimmunoblastic T-cell lymphoma 
and Hodgkin’s disease [79]. Tumour giant cells have been reported before in a paediatric 
case series of PBL [75]. However, multinucleated giant cells identified in the current study in 
gastrointestinal PBL are a new finding.    
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Fifty-nine percent (59 %) of the cases showed immunopositivity with CD45 (LCA) with 
quality of staining predominantly being weak and focal. This is in keeping with findings in 
other reports (2,73]. 
 
All cases in this study cohort showed negative staining with the CD20 antibody. One case 
showed focal weak nuclear staining with PAX5. A minority of cells may show weak staining 
with pan B-cell marker (CD20, PAX5) in some cases and this has been documented in 
literature [2]. 
 
Sixteen out of the seventeen cases (94%) showed negative CD3. Background scattered 
reactive T-lymphocytes were seen in all cases. One case showed aberrant T-cell antigen 
(CD3 and CD4) expression with negative staining for CD2, CD5 and CD8.  
The phenomenon of T-cell infidelity/promiscuity in which PBLs, which are B-cell lymphomas, 
express T-cell antigens is well recognised phenomenon [18,42,43]. CD3 expression in CD20+ 
B-cell lymphomas is usually not problematic since co-expression of these two markers will 
prompt further workup with more lineage-specific markers and molecular studies. However 
in cases when common B-cell antigens (CD20 and PAX5) are negative, T-cell infidelity may 
result in the tumour being classified as a peripheral T-cell lymphoma, not otherwise 
specified (PTCL NOS).  
The proposed possible mechanisms of this lineage ambiguity include trans-differentiation 
and downregulation of B-cell transcription factors (particularly PAX5) [44]. 
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All the cases in the study had at least one plasma cell marker (MUM1, Vs38c, CD138) 
immunopositivity, indicating plasma cell differentiation. MUM1 was the most reliable 
plasma cell marker in this series with 87.5% (14/16) of the cases showing immunopositivity.   
All of the cases in this series which were tested for HHV8 or ALK-1 were negative and this 
helped to distinguish the neoplasm from the other differential diagnoses.  
 
The exact role of EBV in the pathogenesis of PBL is yet to be elucidated. EBER ISH expression 
in the current study, which was confined to PBLs in the gastrointestinal tract of HIV-positive 
patients, showed positivity in only 53% of the cases. This is at variance with rates seen in 
HIV-associated oral cavity and other extra-oral cavity PBLs (60-75%) *2,11,16+. Conflicting 
reports on the association between EBV-infection and gastrointestinal tract PBL have been 
reported in the published case reports and small case series of gastrointestinal PBL.  Luria et 
al *25+ reported on four cases in which all the three cases tested for EBER-ISH were positive.  
Komaranchath et al *23+ reported on four cases in which LMP1 done to assess for EBV co-
infection and only one case was positive. EBER was not done in this case series by 
Komaranchath et al *23+. 
The results in the current study further indicate that EBV infection is not the sole driver of 
this neoplasm. Although the sample size in the present study was small, the findings suggest 
that the EBV infection rates may be lower in the gastrointestinal tract PBLs when compared 
to other extra-oral and oral cavity PBLs. 
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Only two cases had documented molecular study results in the present study cohort. One 
case showed c-MYC rearrangement and the other case showed heavy chain clonality. 
Rearrangements of BCL-2 and BCL-6 were not detected. The case which had c-MYC 
translocation also had EBER ISH positivity. The findings are similar to what has been 
described in other studies [13]. MYC is an oncogene involved in the pathogenesis of 
aggressive haematolymphoid neoplasms and is usually activated by gene translocations 
[80]. MYC translocations are considered the primary genetic event in Burkitt lymphoma (BL) 
and also occur in diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphomas 
with MYC and BCL2 and/or BCL6 rearrangement (double or multi hit lymphomas) [1]. MYC 
rearrangements are associated with poor prognosis [80]. Although MYC rearrangement may 
play a critical role in the pathogenesis of gastrointestinal tract PBL in HIV-positive patients, 
further studies are required to understand the underlying mechanisms. 
 
Accurate diagnosis of PBL and its distinction from other neoplasm which may have different 
management and better prognosis is important. Morphologically, the neoplasms which 
need to be distinguished from gastrointestinal PBL include diffuse large B-cell lymphoma 
(not otherwise specified), ALK + large B-cell lymphoma, extracavitary primary effusion 
lymphoma (PEL), plasmablastic myeloma, poorly differentiated carcinoma (including 
colorectal carcinoma) and melanoma [54]. 
 
Whereas most differentials can be distinguished from PBL based on morphology and 
immunohistochemical profile, plasmablastic myeloma provides a great diagnostic challenge 
and at times is impossible to distinguish from PBL. As a result some have suggested that PBL 
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may actually represent an aggressive form of multiple myeloma or plasmacytoma [61]. The 
presence of a high proliferative index (Ki-67) and EBV infection favours PBL whilst 
immunopositivity for Cyclin D1, CD117 and CD56 favours a plasmablastic myeloma 
[2,63,64]. In attempting to distinguish the two entities, correlation with clinical and 
radiological findings is critical [71]. 
 
 
6.1. Limitation of the Study  
 
 
The study met several challenges during its operation which affected the quality of the 
study in certain aspects. This was a single-centre; laboratory based retrospective study with 
a relatively small number of cases. 
 
Due to lack of clinical correlation, the exact location of the primary disease could not be 
confirmed. The biopsy site documented on the histopathology report was taken as the 
primary site of the disease and the possibility of PBL occurring concurrently at other sites 
including oral cavity could not be excluded. 
 
In some cases, tissue blocks could not be retrieved or had no tissue available for re-cuts. In 
such cases the haematoxylin and eosin (H/E) slides, had to be re-stained which 
compromised on the quality of slides and subsequent images. 
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Immunohistochemical stains on original sections at the time of diagnosis were done at two 
different laboratories, at different times over a time period spanning ten years. Laboratory 
conditions at the time of diagnosis were different to the conditions at the time of the study. 
The archived IHC stains which were utilised lacked standardisation in-terms of antibody 
clonality, dilution and antigen retrieval methods. This could give rise to some variation in 
the results recorded. The option to use the original slides was due to the financial 
implications which would have resulted from repeating the stains to have single fresh run.   
 
Only two cases had molecular studies documented in the histopathology reports and 
laboratory records. The other cases in the study did not have cytogenetic analysis done 
(11/17) or it was unsuccessfully attempted (4/17). The molecular studies for the two cases 
were documented and images captured with Cytovision 4.0 (Leica Biosystems Inc, Buffalo 
Grove, IL, USA).  However the images could not be retrieved successfully as the computer 
was corrupted.  The hard copies of the images were of poor quality and could not be copied. 
Four cases had molecular studies attempted unsuccessfully.  
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CHAPTER 7 
 
 
 
7. CONCLUSION AND RECOMMENDATION 
 
 
This study represented the largest case series of gastrointestinal tract plasmablastic 
lymphomas published to date. 
 
The study confirmed that gastrointestinal tract PBLs have similar sex distribution (male 
predominance), histomorphology and immunophenotype to that of oral and anorectal 
plasmablastic lymphoma. However, the stomach, small intestine and colon being 
uncommon locations, requires a high index of suspicion for an early accurate diagnosis and 
avoidance of potential diagnostic errors. 
 
We have also described additional observations not previously described or emphasised in 
literature which includes pseudo-alveolar growth pattern, centroblast-predominance, 
multinucleated giant cells and clear cell change. 
 
 The study also provides evidence that EBV infection is not the sole driver in the 
pathogenesis of this neoplasm. The EBV infection showed less frequent association with the 
gastrointestinal tract PBL when compared to oral PBLs.  Further research aimed at 
elucidating the true relationship between HIV/AIDS, EBV infection and PBL of the 
gastrointestinal tract in a detailed histopathology, molecular pathology and virology studies 
is recommended. 
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MYC rearrangement may play a pivotal role in the aetiopathogenesis of gastrointestinal 
tract PBL in HIV-positive patients, but further studies are required to understand the 
underlying mechanisms. 
 
Differential diagnoses which show overlapping histopathological and immunological 
features with gastrointestinal tract PBL should always be considered. Clinicopathological 
correlation with clinical findings, imaging studies, histomorphological features, 
immunophenotype and EBV status are critical for establishment of an accurate diagnosis. 
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APPENDIX 4: Data Collecting Sheet 
 
 
 
                                                                              DATA SHEET 
Age: 
Sex:                                Race:                             
Primary   Localisation   
Nature of Specimen  Incision                           Excision  
Tumour Measurements  
Architecture 
Growth Pattern Diffuse Nests/Multinodular Single Cell 
Necrosis None Patchy Extensive 
Starry Sky Yes No  
Other Features    
Cytomorphology  
Cytology Immunoblastic Plasmablastic Centroblastic Plasmacytic  
Apoptosis None Single Cell Confluent  
Paranuclear Hof Yes No   
Mitotic Count  Cytoplasm  Ampho          Eosino      Baso 
Immunohistochemical profile 
Immuno CD45 CD20 CD3 CD79a PAX5 MUM1 Vs38c EMA ALK-1 CD56 CD30 Ki-67 
Result             
HHV8       MNF116       AE1/3       CAM5.2       PLAP       CD2      CD4       CD5       CD7        K/L 
EBER      Positive           Negative   
Translocations  
 Translocation 
IgH  
c-MYC  
BCL-2  
BCL-6  
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APPENDIX 5: Summary of Clinicopathological Features 
 
 
ID AGE RACE SEX SITE OF SPECIMEN Nature of specimen Size (cm) Growth Other PCd EBER CD3 CD20 MUM1 VS38c CD138 HHV8 ALK Ki-67 CK Molecular
1 33 B F Small Intestine Excision Biopsy 3 Diffuse No Positive Positive Negative Positive Positive ND Negative Negative 95% Negative ND
2 42 B M Colon Incision Biopsy Diffuse Nests No Positive Negative Negative Positive Positive ND Negative Negative ND Negative ND
3 29 B F Small Intestine Excision Biopsy 5.5 Diffuse No Positive Negative Negative Positive Positive ND ND Negative 99% ND ND
4 36 B F Stomach Incision Biopsy Diffuse Single CellsYes Positive Negative Negative Positive Positive ND Negative ND 90% ND ND
5 41 B M Stomach Incision Biopsy Diffuse No Negative Negative Negative Positive Positive ND ND ND ND ND US
6 53 B M Colon Excision Biopsy 8 Nests Single CellsYes Negative Negative Negative Positive Positive ND Negative Negative 95% ND ND
7 53 B M Colon Excision Biopsy 1.3 Nests Single CellsYes Negative Negative Negative Positive Negative ND Negative ND 95% Negative US
8 41 B M Colon Excision Biopsy 7 Diffuse No Negative Negative Negative Positive Negative ND Negative Negative 99% ND US
9 49 B M Stomach Excision Biopsy 5 Diffuse PseudoalveolarN Negative Negative Negative Positive Positive Positive ND Negative 95% ND ND
10 37 B M Stomach Incision Biopsy Single Cells Yes Positive Negative Negative Positive Positive ND Negative Negative 100% ND IgH Clonality
11 NA B M Colon Incision Biopsy Diffuse TrabeculaeNo Negative Negative Negative Positive ND ND Negative ND ND ND c-MYC 
12 42 B M Small bowel Excision Biopsy 4 Diffuse PseudoalveolarN Positive Negative Negative Positive ND Positive ND ND 95% Negative US
13 33 B M Small bowel Excision Biopsy Diffuse No Negative Negative Negative Positive ND Positive ND ND 95% ND US
14 29 B F Colon Incision Biopsy TrabeculaeDiffuse No Positive Negative Negative ND Positive Positive ND Negative 96% Negative ND
15 68 B M Stomach Incision Biopsy Diffuse Nests No Positive Negative Negative Negative Positive Positive ND ND 99% Negative ND
16 41 B M Colon Incision Biopsy Diffuse TrabeculaeNo Positive Negative Negative Positive Positive Positive ND Negative ND ND ND
17 29 B F Stomach Incision Biopsy Diffuse Single CellsYes Negative Negative Negative Positive Negative Positive ND Negative 95% Negative ND
PCd-Plasmacytic Differentiation         ND -Not Done US-Unsuccessful CK-Cytokeratins
